A genetic variant that protects the heart against cardiovascular disease has been discovered by researchers at the Wellcome Trust Sanger Institute and their collaborators. Reported today (26th May 2017) in Nature Communications, the cardioprotective variant was found in an isolated Greek population, who are known to live long and healthy lives despite having a diet rich in animal fat.
In Mylopotamos, northern Crete the population are unusual as they have a diet that is rich in animal fat and should cause health complications, yet they have good health and live to an old age.
In an attempt to solve the puzzle, scientists made a genetic portrait of the population by sequencing the entire genome of 250 individuals to get an in-depth view. This was the first time Mylopotamos villagers had their whole genome sequenced. The team then used the results to give a more detailed view of approximately 3,200 people for whom previous genetic information was known.
Scientists discovered a new genetic variant that was not previously known to have cardioprotective qualities. The variant, rs145556679*, was associated with lower levels of both 'bad' natural fats - triglycerides - and 'bad' cholesterol - very low density lipoprotein cholesterol (VLDL). These factors lower the risk of cardiovascular disease.
The cardioprotective variant may be almost unique to the Mylopotamos population. The genome sequencing results of a few thousand Europeans has only revealed one copy of this variant in a single individual in Tuscany, Italy. A separate variant in the same gene has also been found to be associated with lower levels of triglycerides in the Amish founder population in the United States.
Lorraine Southam, joint first author from the Wellcome Trust Sanger Institute, said: "By studying isolated populations, we are able to identify those genetic variants that are at a higher frequency compared to cosmopolitan populations and this in turn increases our power to detect if these variants are disease causing. With isolated populations, we can get a unique view into rare genetic variants that play important roles in complex human diseases."
The combination of genetic data from isolated populations presented statistical complications due to the relatedness of individuals. In this study, scientists designed new software called METACARPA to address these statistical challenges.
Arthur Gilly, joint first author from the Wellcome Trust Sanger Institute, said: "METACARPA was specifically designed to work well on shared data. This new software is able to utilise summary data to detect relatedness of individuals or even overlap of data sets and account for it, therefore making the study more robust."
The team also studied an isolated population from mountainous villages in the Pomak region of northern Greece. Scientists studied the genetics of 1700 people in the population. They discovered four separate genetic variants that affect diastolic blood pressure, fasting glucose levels, white blood cell count and haemoglobin levels.
Lead author, Professor Eleftheria Zeggini from the Wellcome Trust Sanger Institute said: "This study shows the importance of looking at the entire genome to better understand the genetic architecture of a population. We are finding new genetic variants we haven't seen before. We have discovered a medically relevant genetic variant for traits related to cardiovascular disease, the most common cause of death worldwide."
Notes to Editors:
*Genetic variant, rs145556679
rs145556679 resides within an intron of the Down syndrome cell adhesion molecule like 1 (DSCAML1) gene, which is involved in cell adhesion in neuronal processes and is expressed in heart, liver, pancreas, skeletal muscle, kidney and brain. This new genetic variant adds to the growing list of cardioprotective variants found in this isolated population. http://www.
METACARPA is a tool that performs scalable meta-analysis between genetic association studies, both effect-size based and p-value based, while correcting for unknown sample overlap. http://www.
Funding: This work was supported by Wellcome and the European Research Council.
The Wellcome Trust Sanger Institute
The Wellcome Trust Sanger Institute is one of the world's leading genome centres. Through its ability to conduct research at scale, it is able to engage in bold and long-term exploratory projects that are designed to influence and empower medical science globally. Institute research findings, generated through its own research programmes and through its leading role in international consortia, are being used to develop new diagnostics and treatments for human disease. http://www.
Wellcome exists to improve health for everyone by helping great ideas to thrive. We're a global charitable foundation, both politically and financially independent. We support scientists and researchers, take on big problems, fuel imaginations and spark debate. http://www.